{"title":"Biological Agents for Psoriasis Management in HIV-Positive Patients: A Literature Review","authors":"Miaoqi Qiu, Bo Feng, Chengyao Zhu, Lunfei Liu","doi":"10.1155/dth/2370807","DOIUrl":null,"url":null,"abstract":"<div>\n <p>The management of HIV-positive psoriasis patients places a heavy burden on the healthcare system, as there are no standard treatment regimens for these patients and the use of biologics has only been reported sporadically. Here, we conducted a systematic review over the past six years and identified 22 articles containing 34 patients treated with inhibitors against tumor necrosis factor alpha (TNF-<i>α</i>), interleukin (IL)-12/23, IL-17, or IL-23. Our analysis focuses on the effectiveness and safety profile of biological agents, highlighting IL-23 inhibitor’s superior clinical response and tolerability for plaque psoriasis in concomitant HIV-positive patients. Therefore, we suggest IL-23 inhibitor as a promising treatment option for moderate-to-severe psoriasis in HIV-positive patients.</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2370807","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/2370807","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The management of HIV-positive psoriasis patients places a heavy burden on the healthcare system, as there are no standard treatment regimens for these patients and the use of biologics has only been reported sporadically. Here, we conducted a systematic review over the past six years and identified 22 articles containing 34 patients treated with inhibitors against tumor necrosis factor alpha (TNF-α), interleukin (IL)-12/23, IL-17, or IL-23. Our analysis focuses on the effectiveness and safety profile of biological agents, highlighting IL-23 inhibitor’s superior clinical response and tolerability for plaque psoriasis in concomitant HIV-positive patients. Therefore, we suggest IL-23 inhibitor as a promising treatment option for moderate-to-severe psoriasis in HIV-positive patients.
期刊介绍：
Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
